Evaluering af det probiotiske Lactobacillus Coryniformis K8 om COVID-19-forebyggelse hos sundhedsarbejdere
Multicentrisk undersøgelse for at vurdere effekten af indtagelse af Lactobacillus Coryniformis K8 på sundhedspersonale udsat for COVID-19
The aim of the present study is to evaluate the effects of Lactobacillus coryniformis K8 consumption on the incidence and severity of Covid-19 in health workers exposed to the virus. This is a preventive study
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Granada
-
Granada, Granada, Spanien, 18016
- Raquel Rodriguez Blanque
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Persons over 20 years of age.
- Active healthcare personnel, who attend patients with COVID-19 disease, including all professional categories, medicine, nursing and warders.
- Ability to complete surveys.
- Signature of informed consent
Exclusion Criteria:
- Person with positive test of COVID-19 confirmed by PCR test or serology
- Person with concomitant pathology HIV, transplant, active oncology or other type of active immunosuppression
- Pregnant women or women with intention to become pregnant in the next 2 months.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Probiotic
Experimental group who will receive one capsule of Lactobacillus K8 per day (3x10^9 cfu/day). |
The probiotic group will received one capsule with Lactobacillus K8 per day (3x10^9 cfu/day) during 2 months |
|
Placebo komparator: Control
Control group who will receive a daily placebo capsule consisting of maltodextrin |
The control group will received one placebo capsule per day during 2 months |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of SARS CoV-2 infection in healthcare workers
Tidsramme: 8 weeks
|
The incidence of SARS CoV-2 infection will be confirmed by PCR or antigen test |
8 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of hospital admissions caused by SARS-CoV-2 infection
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will required hospital admission because of Covid-19 |
8 weeks
|
|
Incidence of ICU admissions caused by SARS-CoV-2 infection
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will required ICU admission because of Covid-19 |
8 weeks
|
|
Incidence of pneumonia caused by SARS-CoV-2 infection
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will develop pneumonia because of Covid-19 |
8 weeks
|
|
Incidence of oxygen support requirement caused by SARS-CoV-2 infection
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will require oxygen support because of Covid-19 |
8 weeks
|
|
Incidence of gastrointestinal symptoms caused by SARS-CoV-2 infection
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will develop gastrointestinal symptoms because of Covid-19 |
8 weeks
|
|
Days with body's temperature > 37.5 ºC
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with body's temperature > 37.5 ºC during the course of the disease |
8 weeks
|
|
Days with cough
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with cough during the course of the disease |
8 weeks
|
|
Days with fatigue
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with fatigue during the course of the disease |
8 weeks
|
|
Medical treatment
Tidsramme: 8 weeks
|
Use of drugs (dosis and duration of the treatment) for Covid-19 treatment |
8 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Luftvejsinfektioner
- Infektioner
- RNA-virusinfektioner
- Virussygdomme
- Luftvejssygdomme
- Lungesygdomme
- Lungebetændelse, viral
- Lungebetændelse
- Coronavirus infektioner
- Coronaviridae infektioner
- Nidovirales infektioner
- COVID-19
- Kosttilskud
- Mad
- Diæt, mad og ernæring
- Fysiologiske fænomener
- Mad og drikkevarer
- Probiotika
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- P054
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .